Briggs Morrison has bought stock on 7 days since May 2019

Briggs Morrison, M.D. is a Lead Independent Director at Arvinas, Inc. (NASDAQ: ARVN), having joined the board in June 2018 and assuming the lead role in June 2023.( A seasoned medical oncologist with over 30 years in pharmaceuticals and biotechnology, he currently serves as Chief Executive Officer and Board member at Crossbow Therapeutics, Inc. since 2022, and joined the Board of CRISPR Therapeutics in June 2025.( His career highlights include executive positions at Syndax Pharmaceuticals, AstraZeneca PLC, Pfizer Inc., and Merck & Co., Inc., where he oversaw clinical development from Phase 1 to approval for drugs like Tagrisso, Imfinzi, and Lynparza.(

Dr. Morrison holds a B.S. in Biology from Georgetown University and an M.D. from the University of Connecticut.( As of recent filings, he owns 76,021 shares of Arvinas stock valued at over $917,573, and on September 22, 2025, purchased 30,000 additional shares for $227,010 near the 52-week low.(

Written by Perplexity from public sources.